Tags

Type your tag names separated by a space and hit enter

Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma.
J Cardiovasc Pharmacol. 2006 Apr; 47(4):542-8.JC

Abstract

The aim of our study was to assess the effect of various regimens and doses of hormone therapy and tibolone on the Atherogenic Index of Plasma (AIP). A total of 519 postmenopausal women attending our menopause clinic were studied in a prospective design. Women with climacteric symptoms were randomly assigned to receive 1 of the following regimens: tibolone 2.5 mg, conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA), 17beta-estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA), or 17beta-estradiol 1 mg plus norethisterone acetate 0.5 mg (low E2/NETA). Serum parameters were assessed at baseline and after 6 months and included total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoprotein A1 and apolipoprotein B. The AIP was assessed as the log (triglycerides [mmol/L]/HDL-C [mmol/L]). CEE/MPA treatment associated with lower mean LDL-C but higher mean triglyceride levels (-15.5 mg/dL +/- 3.6, P = 0.0001; 12.6 mg/dL +/- 4.8, P = 0.01). Furthermore, CEE/MPA treatment resulted in higher AIP levels (0.073 +/- 0.021, P = 0.001). On the contrary, both E2/NETA regimens and tibolone associated with lower mean triglyceride and HDL-C levels (E2/NETA, triglycerides: -9.8 mg/dL +/- 5.0, P = 0.049; HDL-C: -4.9 mg/dL +/- 1.8, P = 0.01, low E2/NETA triglycerides: -12.5 mg/dL +/- 4.1, P = 0.003; HDL-C: -4.7 mg/dL +/- 1.3, P = 0.001; tibolone, triglycerides: -21.9 mg/dL +/- 2.7, P = 0.0001; HDL-C: -12.7 mg/dL +/- 1.1, P = 0.0001). None of the 3 regimens had any effect on AIP. The effect of a particular regimen of hormone therapy on the lipid-lipoprotein profile differs depending on the parameter assessed. The use of unified markers such as AIP will be helpful in evaluating the overall effect of lipid-lipoprotein modulation on the cardiovascular system. In fact, the concurrent assessment of the therapy effect on both LDL-C and AIP may be more dependable in evaluating the cardiovascular impact of a given regimen.

Authors+Show Affiliations

Second Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16680067

Citation

Christodoulakos, George E., et al. "Differential Effect of Hormone Therapy and Tibolone On Lipids, Lipoproteins, and the Atherogenic Index of Plasma." Journal of Cardiovascular Pharmacology, vol. 47, no. 4, 2006, pp. 542-8.
Christodoulakos GE, Lambrinoudaki IV, Economou EV, et al. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. J Cardiovasc Pharmacol. 2006;47(4):542-8.
Christodoulakos, G. E., Lambrinoudaki, I. V., Economou, E. V., Papadias, C., Panoulis, C. P., Kouskouni, E. E., Vlachou, S. A., & Creatsas, G. C. (2006). Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. Journal of Cardiovascular Pharmacology, 47(4), 542-8.
Christodoulakos GE, et al. Differential Effect of Hormone Therapy and Tibolone On Lipids, Lipoproteins, and the Atherogenic Index of Plasma. J Cardiovasc Pharmacol. 2006;47(4):542-8. PubMed PMID: 16680067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. AU - Christodoulakos,George E, AU - Lambrinoudaki,Irene V, AU - Economou,Emmanuel V, AU - Papadias,Constantinos, AU - Panoulis,Constantinos P, AU - Kouskouni,Evangelia E, AU - Vlachou,Sofia A, AU - Creatsas,George C, PY - 2006/5/9/pubmed PY - 2006/10/25/medline PY - 2006/5/9/entrez SP - 542 EP - 8 JF - Journal of cardiovascular pharmacology JO - J Cardiovasc Pharmacol VL - 47 IS - 4 N2 - The aim of our study was to assess the effect of various regimens and doses of hormone therapy and tibolone on the Atherogenic Index of Plasma (AIP). A total of 519 postmenopausal women attending our menopause clinic were studied in a prospective design. Women with climacteric symptoms were randomly assigned to receive 1 of the following regimens: tibolone 2.5 mg, conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA), 17beta-estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA), or 17beta-estradiol 1 mg plus norethisterone acetate 0.5 mg (low E2/NETA). Serum parameters were assessed at baseline and after 6 months and included total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoprotein A1 and apolipoprotein B. The AIP was assessed as the log (triglycerides [mmol/L]/HDL-C [mmol/L]). CEE/MPA treatment associated with lower mean LDL-C but higher mean triglyceride levels (-15.5 mg/dL +/- 3.6, P = 0.0001; 12.6 mg/dL +/- 4.8, P = 0.01). Furthermore, CEE/MPA treatment resulted in higher AIP levels (0.073 +/- 0.021, P = 0.001). On the contrary, both E2/NETA regimens and tibolone associated with lower mean triglyceride and HDL-C levels (E2/NETA, triglycerides: -9.8 mg/dL +/- 5.0, P = 0.049; HDL-C: -4.9 mg/dL +/- 1.8, P = 0.01, low E2/NETA triglycerides: -12.5 mg/dL +/- 4.1, P = 0.003; HDL-C: -4.7 mg/dL +/- 1.3, P = 0.001; tibolone, triglycerides: -21.9 mg/dL +/- 2.7, P = 0.0001; HDL-C: -12.7 mg/dL +/- 1.1, P = 0.0001). None of the 3 regimens had any effect on AIP. The effect of a particular regimen of hormone therapy on the lipid-lipoprotein profile differs depending on the parameter assessed. The use of unified markers such as AIP will be helpful in evaluating the overall effect of lipid-lipoprotein modulation on the cardiovascular system. In fact, the concurrent assessment of the therapy effect on both LDL-C and AIP may be more dependable in evaluating the cardiovascular impact of a given regimen. SN - 0160-2446 UR - https://www.unboundmedicine.com/medline/citation/16680067/Differential_effect_of_hormone_therapy_and_tibolone_on_lipids_lipoproteins_and_the_atherogenic_index_of_plasma_ L2 - https://doi.org/10.1097/01.fjc.0000211747.16573.d5 DB - PRIME DP - Unbound Medicine ER -